Raymond James Financial Inc. Acquires New Holdings in Guardant Health, Inc. (NASDAQ:GH)

Raymond James Financial Inc. acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 72,364 shares of the company's stock, valued at approximately $2,211,000. Raymond James Financial Inc. owned approximately 0.06% of Guardant Health at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of GH. R Squared Ltd purchased a new position in shares of Guardant Health in the fourth quarter worth $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health in the fourth quarter valued at about $43,000. Kimelman & Baird LLC bought a new position in shares of Guardant Health during the fourth quarter valued at about $58,000. Quantbot Technologies LP purchased a new stake in shares of Guardant Health during the fourth quarter worth about $80,000. Finally, Jones Financial Companies Lllp grew its stake in shares of Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after purchasing an additional 817 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GH shares. Mizuho assumed coverage on Guardant Health in a research note on Thursday, April 10th. They set an "outperform" rating and a $55.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Barclays raised their price objective on Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, May 1st. Guggenheim reiterated a "buy" rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Finally, Stephens reissued an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. Twenty-one equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Guardant Health has an average rating of "Buy" and a consensus price target of $51.86.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the transaction, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. The trade was a 4.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 107,132 shares of company stock valued at $5,249,355. 5.50% of the stock is owned by corporate insiders.

Guardant Health Stock Down 0.5 %

GH stock traded down $0.23 during midday trading on Tuesday, hitting $43.83. The company's stock had a trading volume of 376,198 shares, compared to its average volume of 2,347,176. Guardant Health, Inc. has a 12 month low of $18.01 and a 12 month high of $52.92. The company has a 50 day moving average of $43.76 and a two-hundred day moving average of $38.51. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of -12.32 and a beta of 1.49.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Guardant Health's quarterly revenue was up 20.8% on a year-over-year basis. During the same period last year, the company posted ($0.46) earnings per share. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.